| |
6 month follow-up |
12 month follow-up |
| a. Weekly vision self-monitoring |
OR |
95% CI |
P-value |
OR |
95% CI |
P-value |
| VMS group vs. Control group |
7.12 |
(2.68,18.9) |
<0.001* |
4.18 |
(1.68,10.4) |
0.002* |
| Age (years) |
0.97 |
(0.91,1.02) |
0.22 |
0.96 |
(0.91,1.02) |
0.19 |
| Female Gender |
1.00 |
(0.40,2.5) |
0.99 |
1.35 |
(0.53,3.4) |
0.53 |
| VA better eye (logMAR) |
0.75 |
(0.03,16.8) |
0.85 |
2.02 |
(0.07,62.7) |
0.69 |
| VA worse eye (logMAR) |
0.39 |
(0.07,2.2) |
0.28 |
1.21 |
(0.21,6.8) |
0.83 |
| AMD type (intermediate both eyes) |
1.27 |
(0.32,5.1) |
0.73 |
1.31 |
(0.35,4.9) |
0.69 |
| AMD type (intermediate one eye) |
0.57 |
(0.11,2.9) |
0.50 |
1.30 |
(0.26,6.5) |
0.75 |
| Perceived Stress Scale Score |
1.13 |
(0.95,1.35) |
0.18 |
0.94 |
(0.80,1.11) |
0.48 |
| NY/CT Retina Specialists vs. JHU |
4.69 |
(1.5,14.3) |
0.007* |
2.42 |
(0.85,6.9) |
0.10 |
| Retirement communities vs. JHU |
6.58 |
(0.68,63.4) |
0.10 |
3.75 |
(0.39,35.8) |
0.25 |
| b. No confidence in self-monitoring |
OR |
95% CI |
P-value |
OR |
95% CI |
P-value |
| VMS group vs. Control group |
0.15 |
(0.06,0.38) |
<0.001* |
0.20 |
(0.07,0.56) |
0.002* |
| Age (years) |
1.03 |
(0.98,1.09) |
0.27 |
1.09 |
(1.02,1.16) |
0.016* |
| Female Gender |
1.35 |
(0.56,3.22) |
0.51 |
0.99 |
(0.37,2.7) |
0.997 |
| VA better eye |
0.90 |
(0.05,17.02) |
0.94 |
8.24 |
(0.22,308.4) |
0.25 |
| VA worse eye |
1.33 |
(0.28,6.4) |
0.73 |
0.44 |
(0.07,2.9) |
0.39 |
| AMD type (intermediate both eyes) |
2.41 |
(0.62,9.5) |
0.21 |
0.44 |
(0.11,1.8) |
0.26 |
| AMD type (intermediate one eye) |
2.32 |
(0.48,11.1) |
0.29 |
0.99 |
(0.19,5.2) |
1.0 |
| Perceived stress scale score |
0.90 |
(0.77,1.05) |
0.18 |
1.14 |
(0.96,1.36) |
0.14 |
| NY/CT Retina Specialists vs. JHU |
0.58 |
(0.21,1.62) |
0.30 |
0.92 |
(0.28,2.96) |
0.88 |
| Retirement communities vs. JHU |
0.29 |
(0.04,2.4) |
0.25 |
0.35 |
(0.03,3.9) |
0.40 |
aAdjusted model includes all variables
*Statistically significant (p<0.05) |
